SMALL CELL LUNG CANCER (SCLC)

This phase 2 trial tests different doses of tarlatamab, a drug given through an IV, in 252 adults with small cell lung cancer that has worsened after standard treatment. The main goal is to see if the drug can shrink tumors or stop the cancer from growing. Researchers will also m…

This early-phase study tests a new radioactive drug, 225Ac-ABD147, in people with small cell lung cancer or large cell neuroendocrine lung cancer that has spread and was previously treated with platinum chemotherapy. The main goals are to check safety, find the best dose, and see…

This phase 3 study compares tarlatamab, an experimental drug, to standard treatments in about 500 adults with small cell lung cancer that returned after initial chemotherapy. The main goal is to see if tarlatamab helps people live longer. Participants must have measurable disease…

This study tests the drug pembrolizumab in about 1,600 people with various advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink or control the tumors. Participants receive pembrolizumab and are monitored for tumor respons…

This study follows 160 adults with lung cancer to see how changes in muscle mass, strength, and function relate to treatment side effects, quality of life, and survival. Researchers want to understand why some patients struggle to complete their cancer therapy. The goal is to use…

This study follows up to 400 people who previously received A2Bio gene therapy for various solid tumors, including lung, colon, and pancreatic cancers. The goal is to track long-term side effects and see how well the treatment effects last over time. No new treatment is given—par…